Primary Site >> Liver Cancer
Gene >> GPC3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Simpson-Golabi-Behmel Syndrome Type 1 PMID: 20301398 |
Ref: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. PMID: 9371521 |
Ref: A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma. PMID: 9507397 |
Ref: [Expression and significance of MXR7 mRNA in human hepatocellular carcinoma]. PMID: 11829813 |
Ref: Cloning and expression of MXR7 gene in human HCC tissue. PMID: 11819523 |
Ref: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. PMID: 12478660 Ref: Glypican-3 is overexpressed in human hepatocellular carcinoma. PMID: 12824919 Ref: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. PMID: 12851874 Ref: Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling. PMID: 14508064 |
Ref: Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. PMID: 14985104 Ref: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. PMID: 15059894 Ref: Identification of glypican-3 as a novel tumor marker for melanoma. PMID: 15475451 Ref: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. PMID: 15623647 Ref: Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. PMID: 15887976 |
Ref: An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. PMID: 15735714 Ref: Many accurate small-discriminatory feature subsets exist in microarray transcript data: biomarker discovery. PMID: 15826317 Ref: Discovery of a new biomarker for gastroenterological cancers. PMID: 15902956 Ref: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. PMID: 15920546 Ref: Expression and significance of tumor-related genes in HCC. PMID: 15991281 Ref: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. PMID: 16024626 Ref: Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. PMID: 16162153 Ref: Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. PMID: 16227623 Ref: Recent developments in the first detection of hepatocellular carcinoma. PMID: 16450014 |
Ref: Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. PMID: 16489048 Ref: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. PMID: 16675560 Ref: Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. PMID: 16682817 Ref: Gradual upregulation of OCI-5 expression during occurrence and progression of rat hepatocellular carcinoma. PMID: 16698587 Ref: [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells]. PMID: 16772080 Ref: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. PMID: 17063081 Ref: A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. PMID: 17087938 Ref: The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. PMID: 17117158 Ref: [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma]. PMID: 17212093 |
Ref: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. PMID: 17317821 Ref: The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. PMID: 17668883 Ref: Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. PMID: 17763368 |
Ref: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. PMID: 18264086 Ref: Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. PMID: 18300806 Ref: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. PMID: 18318435 Ref: Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. PMID: 18337085 Ref: Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. PMID: 18413366 Ref: HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. PMID: 18425324 Ref: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. PMID: 18480006 Ref: Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. PMID: 18628090 Ref: Glypican-3 is expressed in chromophobe renal cell carcinomas. PMID: 18655366 Ref: [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma]. PMID: 18974622 Ref: Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. PMID: 18976006 Ref: Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. PMID: 19047163 |
Ref: Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. PMID: 19022220 Ref: The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. PMID: 19141032 Ref: Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. PMID: 19212669 Ref: The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. PMID: 19231003 Ref: Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. PMID: 19243386 Ref: Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages. PMID: 19276671 Ref: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. PMID: 19496787 Ref: Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. PMID: 19513517 Ref: Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. PMID: 19517479 Ref: Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. PMID: 19550373 Ref: Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation. PMID: 19574424 Ref: Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. PMID: 19838081 |
Ref: Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. PMID: 19246079 Ref: Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. PMID: 19793164 Ref: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. PMID: 19816934 Ref: SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. PMID: 20182341 Ref: Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. PMID: 20372847 Ref: Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. PMID: 20374302 Ref: Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. PMID: 20444424 Ref: Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma. PMID: 20444731 Ref: Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. PMID: 20501450 Ref: Molecular diagnosis of multistage hepatocarcinogenesis. PMID: 20603246 Ref: Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. PMID: 20653060 Ref: The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. PMID: 20725905 Ref: Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells. PMID: 20803547 Ref: Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. PMID: 20812357 Ref: Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. PMID: 20845507 Ref: Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. PMID: 20847643 Ref: Expression of glypican 3 in placental site trophoblastic tumor. PMID: 20868507 Ref: [Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma]. PMID: 20960882 Ref: Up-regulation of glypican-3 in human hepatocellular carcinoma. PMID: 21187490 |
Ref: Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. PMID: 20964802 Ref: Annexin A2 as a differential diagnostic marker of hepatocellular tumors. PMID: 20971570 Ref: Glypican-3: a new target for cancer immunotherapy. PMID: 21112773 Ref: HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. PMID: 21281401 Ref: Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. PMID: 21303616 Ref: EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. PMID: 21330577 Ref: Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. PMID: 21371925 Ref: [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma]. PMID: 21429352 Ref: Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinoma. PMID: 21443783 Ref: GPC3 fused to an alpha epitope of HBsAg acts as an immune target against hepatocellular carcinoma associated with hepatitis B virus. PMID: 21459723 Ref: Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. PMID: 21520170 Ref: Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. PMID: 21554204 Ref: Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. PMID: 21617840 Ref: Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. PMID: 21668581 Ref: Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. PMID: 21847365 Ref: A new membrane re-anchored protein originating from GPC3 against hepatoma cells HepG2. PMID: 21904776 Ref: Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. PMID: 21919070 Ref: Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. PMID: 21942912 Ref: Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. PMID: 22087143 Ref: [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma]. PMID: 22177248 Ref: The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. PMID: 22563565 Ref: Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. PMID: 22820138 Ref: Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3. PMID: 29403695 |
Ref: Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. PMID: 21655958 Ref: Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. PMID: 21822558 Ref: Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. PMID: 21922136 Ref: Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. PMID: 21937079 Ref: Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. PMID: 22119409 Ref: Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. PMID: 22287594 Ref: Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. PMID: 22382024 Ref: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. PMID: 22449976 Ref: Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. PMID: 22564378 Ref: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. PMID: 22577059 Ref: Gene expression profiling of liver cancer stem cells by RNA-sequencing. PMID: 22606345 Ref: Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. PMID: 22654434 Ref: Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. PMID: 22706665 Ref: High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. PMID: 22820551 Ref: Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma. PMID: 22956868 Ref: Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma. PMID: 23052165 Ref: Conditioned media from (pre)adipocytes stimulate fibrinogen and PAI-1 production by HepG2 hepatoma cells. PMID: 23208413 Ref: A glypican-3-derived peptide vaccine against hepatocellular carcinoma. PMID: 23243625 Ref: Preparation and characterization of monoclonal antibody against glypican-3. PMID: 23244326 Ref: [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy]. PMID: 23259386 Ref: The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma. PMID: 23667740 |
Ref: A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. PMID: 22865282 Ref: Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. PMID: 23060277 Ref: Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. PMID: 23079207 Ref: Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. PMID: 23305321 Ref: Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. PMID: 23354275 Ref: First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. PMID: 23362325 Ref: Highly specific and ultrasensitive graphene-enhanced electrochemical detection of low-abundance tumor cells using silica nanoparticles coated with antibody-conjugated quantum dots. PMID: 23402311 Ref: Peptide vaccines for hepatocellular carcinoma. PMID: 23442593 Ref: Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case. PMID: 23466818 Ref: Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. PMID: 23471984 Ref: Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. PMID: 23526389 Ref: A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. PMID: 23537217 Ref: Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. PMID: 23601901 Ref: Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. PMID: 23643963 Ref: [Relationship between glypican-3 and Notch1 expressions in hepatocellular carcinoma]. PMID: 23644127 Ref: [Preparation and in vitro study of a high molecular weight contrast agent targeting hepatoma cells]. PMID: 23663764 Ref: Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. PMID: 23686365 Ref: Multifocal hepatic neoplasia in 3 children with APC gene mutation. PMID: 23715166 Ref: A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. PMID: 23743582 Ref: Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. PMID: 23868000 Ref: Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican3derived peptide. PMID: 23903757 Ref: Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. PMID: 24186850 Ref: Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology. PMID: 24207089 Ref: Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (DeltaNp63) in squamous cell and urothelial carcinoma. PMID: 24225756 Ref: Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. PMID: 24250310 Ref: New genetic markers for diagnosis of hepatitis C related hepatocellular carcinoma in Egyptian patients. PMID: 24369324 Ref: Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? PMID: 24460300 |
Ref: Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. PMID: 23532638 Ref: MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3. PMID: 23607462 Ref: Glypican-3 antibodies: a new therapeutic target for liver cancer. PMID: 24140348 Ref: Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. PMID: 24252799 Ref: Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. PMID: 24433439 Ref: The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. PMID: 24439425 Ref: Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PMID: 24454751 Ref: Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. PMID: 24492943 Ref: Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. PMID: 24496449 Ref: Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma. PMID: 24498024 Ref: Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. PMID: 24521523 Ref: Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. PMID: 24548704 Ref: Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. PMID: 24627434 Ref: Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. PMID: 24672660 Ref: Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice. PMID: 24690765 Ref: [Preparation of a glypican-3-targeting hepatocellular carcinoma MR probe and its molecular imaging in HepG2 cells]. PMID: 24735598 Ref: Imaging of hepatocellular carcinoma patient-derived xenografts using (8)(9)Zr-labeled anti-glypican-3 monoclonal antibody. PMID: 24836949 Ref: Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. PMID: 24876756 Ref: GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. PMID: 24901124 Ref: A sensitive method for protein assays using a peptide-based nano-label: human glypican-3 detection for hepatocellular carcinomas diagnosis. PMID: 24909227 Ref: Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. PMID: 24914343 Ref: [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors]. PMID: 24915815 Ref: Circulating biomarkers in hepatocellular carcinoma. PMID: 24923562 Ref: Lentivirus vectors construction of SiRNA targeting interference GPC3 gene and its biological effects on liver cancer cell lines Huh-7. PMID: 25129460 Ref: Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. PMID: 25195714 Ref: Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. PMID: 25270552 Ref: Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. PMID: 25320357 Ref: Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. PMID: 25359880 Ref: Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. PMID: 25378766 Ref: Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. PMID: 25446613 Ref: Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. PMID: 27508174 |
Ref: Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma. PMID: 24687454 Ref: Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver. PMID: 25108409 Ref: Glypican 3 expression in pediatric malignant solid tumors. PMID: 25344940 Ref: Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. PMID: 25354479 Ref: Glypican 3 overexpression in primary and metastatic Wilms tumors. PMID: 25366870 Ref: Reevaluation of glypican-3 as a prognostic marker in HCC using X-tile software. PMID: 25432695 Ref: Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. PMID: 25449037 Ref: Serological tumor markers of hepatocellular carcinoma: a meta-analysis. PMID: 25450646 Ref: Enzyme-free and label-free fluorescence sensor for the detection of liver cancer related short gene. PMID: 25483916 Ref: Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers. PMID: 25542894 Ref: Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. PMID: 25572615 Ref: Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells. PMID: 25625609 Ref: Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling. PMID: 25653284 Ref: Simultaneous double primary clear cell carcinomas of liver and kidney: a case report and review of literature. PMID: 25755808 Ref: High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. PMID: 25784484 Ref: Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma. PMID: 25862856 Ref: Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma. PMID: 25892879 Ref: Expression of Glypican 3 in low and high grade urothelial carcinomas. PMID: 25896897 Ref: Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. PMID: 25929570 Ref: Quantification of glypican 3, beta-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution. PMID: 25939253 Ref: Multifunctional biocompatible graphene oxide quantum dots decorated magnetic nanoplatform for efficient capture and two-photon imaging of rare tumor cells. PMID: 25939643 Ref: Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. PMID: 25955255 Ref: Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells. PMID: 25967456 Ref: Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. PMID: 25987009 Ref: Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions. PMID: 26011625 Ref: T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. PMID: 26052074 Ref: Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions. PMID: 26107238 Ref: Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PMID: 26332121 Ref: Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. PMID: 26406957 Ref: Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis. PMID: 26502856 |
Ref: Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. PMID: 26343958 Ref: Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. PMID: 26522694 Ref: Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. PMID: 26606739 Ref: Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. PMID: 26616051 Ref: Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. PMID: 26641029 Ref: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. PMID: 26755876 Ref: Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients. PMID: 26764243 Ref: Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. PMID: 26850086 Ref: Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response. PMID: 26942076 Ref: CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PMID: 26977595 Ref: Modeling of Hepatocytes Proliferation Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion. PMID: 27074018 Ref: Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. PMID: 27085251 Ref: MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. PMID: 27090017 Ref: Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3. PMID: 27102087 Ref: Targeted nanobubbles in low-frequency ultrasound-mediated gene transfection and growth inhibition of hepatocellular carcinoma cells. PMID: 27216880 Ref: Biofunctionalized magnetic nanospheres-based cell sorting strategy for efficient isolation, detection and subtype analyses of heterogeneous circulating hepatocellular carcinoma cells. PMID: 27240010 Ref: Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas. PMID: 27300354 Ref: GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma. PMID: 27380057 Ref: Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. PMID: 27467945 Ref: Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. PMID: 27498576 Ref: Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. PMID: 27552844 Ref: A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma. PMID: 27563447 Ref: Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. PMID: 27573079 Ref: Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution. PMID: 27601357 Ref: Effect of co-transfection of miR-520c-3p and miR-132 on proliferation and apoptosis of hepatocellular carcinoma Huh7. PMID: 27633306 Ref: Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population. PMID: 27650540 Ref: Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. PMID: 27655712 Ref: Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. PMID: 27667400 Ref: Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. PMID: 27669301 Ref: Peroxidase-like catalytic activity of copper ions and its application for highly sensitive detection of glypican-3. PMID: 27692382 Ref: Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. PMID: 27729630 Ref: GPC-3 in hepatocellular carcinoma: current perspectives. PMID: 27878117 Ref: Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. PMID: 28123387 |
Ref: Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions. PMID: 27276915 Ref: Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. PMID: 27419635 Ref: Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. PMID: 27530312 Ref: Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection. PMID: 27862961 Ref: Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. PMID: 28035063 Ref: Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. PMID: 28035433 Ref: The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. PMID: 28087980 Ref: Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review). PMID: 28098909 Ref: Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). PMID: 28120036 Ref: Nested polymerase chain reaction technique for the detection of Gpc3 and Afp mRNA in liver cancer micrometastases. PMID: 28198497 Ref: Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis. PMID: 28207681 Ref: Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation. PMID: 28276470 Ref: Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. PMID: 28429175 Ref: Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. PMID: 28445973 Ref: Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1. PMID: 28472609 Ref: New tumor suppressor microRNAs target glypican-3 in human liver cancer. PMID: 28476031 Ref: Can glypican-3 be a disease-specific biomarker? PMID: 28510121 Ref: Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy PMID: 28545181 Ref: [A bioinformatics analysis of differentially expressed genes associated with liver cancer]. PMID: 28763861 Ref: MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition. PMID: 28812296 Ref: Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. PMID: 28852111 Ref: T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. PMID: 28856237 Ref: A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. PMID: 28865999 Ref: Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma. PMID: 28869105 Ref: Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. PMID: 28881778 Ref: Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. PMID: 29025594 Ref: Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy. PMID: 29106433 Ref: Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. PMID: 29113314 Ref: Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. PMID: 29123959 Ref: Variety and Dynamics of Proteoforms in the Human Proteome: Aspects of Markers for Hepatocellular Carcinoma. PMID: 29168748 Ref: Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro. PMID: 29203107 Ref: The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma. PMID: 29226636 Ref: A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. PMID: 29259231 Ref: Glypican-3 and Melanoma Antigen Genes 1 and 3 as Tumor Markers for Hepatocellular Carcinoma. PMID: 29708315 |
Ref: Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. PMID: 28621802 Ref: From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. PMID: 28881044 Ref: Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. PMID: 29204748 Ref: Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma. PMID: 29204978 Ref: Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays. PMID: 29271183 Ref: Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells. PMID: 29345911 Ref: Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis. PMID: 29369198 Ref: Autophagy suppresses proliferation of HepG2 cells via inhibiting glypican-3/wnt/beta-catenin signaling. PMID: 29379301 Ref: Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma. PMID: 29381229 Ref: Multi-parameter gene expression profiling of peripheral blood for early detection of hepatocellular carcinoma. PMID: 29391759 Ref: SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma. PMID: 29397868 Ref: Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. PMID: 29398870 Ref: Dual-Selective and Dual-Enhanced SERS Nanoprobes Strategy for Circulating Hepatocellular Carcinoma Cells Detection. PMID: 29521467 Ref: Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. PMID: 29535817 Ref: Polyclonal antibody production against rGPC3 and their application in diagnosis of hepatocellular carcinoma. PMID: 29561231 Ref: Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma. PMID: 29563582 Ref: Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. PMID: 29569872 Ref: Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. PMID: 29623600 Ref: In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe. PMID: 29675356 Ref: Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications. PMID: 29791027 Ref: Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PMID: 29879168 Ref: Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. PMID: 29901640 Ref: Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. PMID: 29916268 Ref: Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. PMID: 29935166 Ref: Elevated GPC3 level promotes cell proliferation in liver cancer. PMID: 29963171 Ref: Both glypican-3/Wnt/beta-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. PMID: 30001951 Ref: Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogen-induced precancerous hepatic lesions to cancer in a murine model. PMID: 30018715 Ref: Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. PMID: 30033270 Ref: A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity. PMID: 30059039 Ref: Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. PMID: 30078052 Ref: Novel GPC3-binding WS2-Ga(3+)-PEG-peptide nanosheets for in vivo bimodal imaging-guided photothermal therapy. PMID: 30091395 Ref: A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. PMID: 30122918 Ref: Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro. PMID: 30127626 Ref: Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments. PMID: 30275801 Ref: Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours. PMID: 30317296 Ref: Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. PMID: 30327605 Ref: Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. PMID: 30347351 Ref: Glypican-3 Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. PMID: 30353932 Ref: Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites. PMID: 30383541 |